Branch Leslie G, Crantford Clayton, Cunningham Teresa, Bharti Gaurav, Thompson James, Couture Dan, David Lisa R
Department of Plastic and Reconstructive Surgery, Wake Forest Baptist Health, Winston-Salem, NC.
J Craniofac Surg. 2017 Jan;28(1):26-29. doi: 10.1097/SCS.0000000000003166.
Resorbable plating in cranial reconstruction for craniosynostosis has fewer reported complications than rigid hardware. Few long-term outcome studies exist for pediatric patients treated with this technology for cranial vault reconstruction.
A retrospective review was performed on pediatric patients undergoing cranial vault reconstruction for craniosynostosis by 3 surgeons over a 15-year period. MacroPore (Cytori Therapeutics, San Diego, CA) or Lactosorb (Walter Lorenz Surgical Inc, Jacksonville, FL), composed of polyglycolic and polylactic acids, was used for resorbable plate fixation.
A total of 203 patients underwent resorbable plate fixation with a mean age of 15.8 months at surgery. Mean length of follow-up was 6.4 years. Lactosorb plating system was used in the majority of patients (74%) compared with MacroPore plating system (26%). Overall, unplanned reoperations were required in 5.4% of patients. Palpable hardware was noticed in 10.3% of patients. Only 3 patients (1.5%) developed exposure of the resorbable hardware requiring removal, all MacroPore plates. Four patients (2%) developed surgical site infection and 3 patients (1.5%) developed a seroma. There were 15.8% requiring later surgical revision with cranial vault expansion or cranioplasty with grafts for residual cranial defects. The majority of revisional reoperations (81%) occurred in the first half of the study before the addition of Allogenix.
Resorbable plating systems, specifically Lactosorb, for cranial reconstruction are a safe, reproducible, inexpensive modality with very low complication rates. They have 3-dimensional stability, rigid fixation without causing growth restriction, and lower likelihood of need for removal.
在颅缝早闭颅骨重建中,可吸收接骨板的并发症报道少于刚性金属接骨板。对于采用该技术进行颅骨穹窿重建的儿科患者,长期疗效研究较少。
对3位外科医生在15年期间为颅缝早闭患者进行颅骨穹窿重建的儿科患者进行回顾性研究。使用由聚乙醇酸和聚乳酸组成的MacroPore(Cytori Therapeutics,圣地亚哥,加利福尼亚州)或Lactosorb(Walter Lorenz Surgical Inc,杰克逊维尔,佛罗里达州)进行可吸收接骨板固定。
共有203例患者接受了可吸收接骨板固定,手术时平均年龄为15.8个月。平均随访时间为6.4年。与MacroPore接骨板系统(26%)相比,大多数患者(74%)使用了Lactosorb接骨板系统。总体而言,5.4%的患者需要进行计划外再次手术。10.3%的患者可触及接骨板。只有3例患者(1.5%)出现可吸收接骨板外露需要取出,均为MacroPore接骨板。4例患者(2%)发生手术部位感染,3例患者(1.5%)出现血清肿。15.8%的患者需要后期手术翻修,进行颅骨穹窿扩张或使用移植物进行颅骨成形术以修复残留颅骨缺损。大多数翻修再次手术(81%)发生在研究的前半期,即在添加Allogenix之前。
用于颅骨重建的可吸收接骨板系统,特别是Lactosorb,是一种安全、可重复、廉价的方式,并发症发生率极低。它们具有三维稳定性、刚性固定且不会导致生长受限,取出的可能性较低。